Fig. 8From: Integrative omics analyses broaden treatment targets in human cancerSummary of multi-omics-based druggability. Bar graphs show the percentages of tumor samples with a drug-associated variant type (mutation, mRNA expression, protein expression) in the cancer-type-specific and cancer-type-non-specific settings. The circular display shows cumulative percentages of tumor samples with drug-associated biomarkers of successively decreasing levels of evidenceBack to article page